Showing results (281-290 of 302) with videos related to

Sort By:
Pageof 31
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
Haematologica|October 5, 2019
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemiaJared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, et al.
American Journal of Hematology|October 10, 2012
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemiaSonia Fabris, Laura Mosca, Giovanna Cutrona, et al.
Blood|August 16, 2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, et al.
Science Translational Medicine|February 16, 2018
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolenceGiovanna Cutrona, Claudio Tripodo, Serena Matis, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic LeukemiaRiccardo Bomben, Francesca Maria Rossi, Filippo Vit, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Pageof 31